Bayer Stock

Bayer Equity

The The Equity of Bayer (BAYN.DE) as of Aug 15, 2026 is 25.95 B EUR. In the previous year, The Equity was 31.91 B EUR — a change of -18.68% (lower).

Equity

25.95 BEUR

YoY

-18.68%

Last updated:

In 2026, Bayer's equity was 25.95 B EUR, a -18.68% increase from the 31.91 B EUR equity in the previous year.

Access this data via the Eulerpool API

Bayer Stock analysis

What does Bayer do? Bayer AG is a German company that was founded in 1863 by Friedrich Bayer and Johann Friedrich Weskott in Wuppertal. The company started out as a manufacturer of dyes, but over time it has evolved into a leading global agrochemical, health, and life science company. Bayer's business model is based on the goal of finding innovative solutions to the societal challenges of the future. This includes promoting agriculture and health, as well as sustainability and the preservation of natural resources. Bayer specializes in three business areas: Pharmaceuticals, Consumer Health, and Crop Science. In the Pharmaceuticals division, Bayer develops and markets innovative drugs for a variety of diseases. The company focuses on research and development in key therapy areas such as cardiology, oncology, hematology, neurology, and immunology. Well-known and successful brands from Bayer in the Pharmaceuticals sector include Xarelto, Kogenate, Stivarga, Eylea, and Nexavar. In the Consumer Health division, Bayer develops and distributes products for consumer health and well-being. This includes self-medication products, dietary supplements, contact lens care products, and animal health products. Well-known brands from Bayer Consumer Health include Aspirin, Bepanthen, Berocca, Coppertone, and Advantage. In the Crop Science division, Bayer develops and markets products and solutions for agriculture. This includes crop protection products, seeds, plant breeding, and digital farming. The goal is to help farmers worldwide operate sustainably and productively to meet the growing demand for food. Well-known brands from Bayer Crop Science include Roundup, Decis, Diflubenzuron, and Dekalb. Bayer is known for its innovative power and has made many inventions and discoveries throughout its history. It was one of the first companies to develop synthetic dyes, and in 1897, it was also the first company in Germany to manufacture Aspirin. Since then, Bayer has made numerous groundbreaking discoveries and is now at the forefront of the pharmaceutical and agrochemical industry. Bayer is headquartered in Leverkusen and operates in over 90 countries worldwide. The company employs over 100,000 people and had a turnover of around 41 billion euros in 2020. The company is also committed to reducing its ecological footprint in line with its business goals and strives to improve sustainability in its value chain. Bayer is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Bayer's Equity

Bayer's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Bayer's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Bayer's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Bayer's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Bayer’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Bayer stock

The Equity of Bayer is 25.95 B EUR in 2026.

The Equity of Bayer changed from 31.91 B EUR to 25.95 B EUR, representing a -18.68% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Bayer since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Bayer historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Bayer

All Key Metrics — Bayer